February 14, 2025
Solar Pharma inks pact with Bayer to promote drug for persistent kidney illness

Bayer has granted non-exclusive rights to Solar Pharma to market and distribute a second Finerenone product

Solar Pharma on January 17 mentioned it has inked a pact with Bayer to market a drug for the remedy of persistent kidney illness amongst others. Below the phrases of the settlement, Bayer has granted non-exclusive rights to Solar Pharma to market and distribute a second Finerenone product underneath the model identify Lyvelsa.

Finerenone was first launched by Bayer underneath the model identify Kerendia in 2022. “This partnership underscores our dedication to make modern medicines accessible to sufferers in India,” Solar Pharma India Enterprise CEO Kirti Ganorkar mentioned in a press release.

Story continues beneath Commercial

Bayer’s Prescribed drugs South Asia Nation Division Head Shweta Rai mentioned with the introduction of a second model of Finerenone in India, by means of a partnership with Solar Pharma, the corporate is advancing its dedication of creating healthcare accessible to as many sufferers as attainable.

“India has a excessive incidence of diabetes and related renal and cardiac circumstances. The true worth of improvements like Finerenone can solely be totally realised after they attain all deserving sufferers,” she added.

Finerenone, a patented medication, is indicated to scale back the chance of sustained eGFR decline, end-stage kidney illness, cardiovascular loss of life, non-fatal myocardial infarction, and hospitalisation for coronary heart failure in grownup sufferers with persistent kidney illness related to kind 2 diabetes mellitus.